Zydus Lifesciences has successfully acquired US-based Assertio Holdings Inc. for $166.4 million in a cash tender offer. This strategic move, completed through its subsidiary Zara Merger Sub Inc., makes Assertio a wholly-owned subsidiary and strengthens Zydus's pipeline of innovative drugs, particularly in specialty and oncology supportive-care therapies.
Zydus Lifesciences has successfully acquired US-based Assertio Holdings Inc. for $166.4 million in a cash tender offer, completed through its subsidiary Zara Merger Sub Inc. This strategic move makes Assertio a wholly-owned subsidiary, significantly strengthening Zydus's…
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.